




Name	Takanori Teshima	
Current Position	Distinguished Professor Hokkaido University	
Country	Japan	
Major Field	GVHD, GVL	

Educational Background

1986 MD, Kyushu Univ, Fukuoka
1997 PhD, Kyushu Univ, Fukuoka
1997 Postdoc fellow, Dana-Farber Cancer Institute, Boston
1999 Postdoc fellow, Univ of Michigan, Ann Arbor

Professional Experience

1996 Assistant Professor, Medicine II. Okayama Univ, Okayama
2000 Research Investigator, Internal Medicine, Univ of Michigan, Ann Arbor
2002 Assistant Professor, Medicine II. Okayama Univ, Okayama
2004 Associate Professor, Center for Cellular & Molecular Medicine, Kyushu Univ
2012 Professor, Hematology, Hokkaido Univ, Sapporo
2023 Distinguished Professor, Hokkaido Univ, Sapporo

Other Experience and Professional Memberships

2014 Executive Director, Japanese Society of Hematology
2015 Executive Director, Japanese Society of Transfusion Medicine & Cell Therapy
2020 President, Japanese Society for Transplantation and Cellular Therapy

Main Scientific Publications

1. Teshima T, et al: Acute GVHD does not require alloantigen expression on host epithelium. Nature Med. 2002.
2. Asakura S, Teshima T, et al: Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest 2010.
3. Takashima S, Teshima T, et al: The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. J Exp Med. 2011.
4. Yamakawa T, Teshima T, et al: Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic GVHD. Blood. 2018.
5. Hayase E, Teshima T, et al: R-Spondin1 expands Paneth cells and prevents dysbiosis induced by GVHD. J Exp Med. 2017.
6. Takahashi S, Teshima T, et al: Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine GVHD. Blood 2018.
7. Toffalori C, Teshima T, et al: Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019.
8. Stein-Thoeringer CK, Teshima T, et al: Lactose drives Enterococcus expansion to promote GVHD. Science. 2019.
9. Zeiser R, Teshima T, et al: Ruxolitinib for Glucocorticoid-Refractory Acute GVHD. N Engl J Med 2020.
10. Peled JU, Teshima T, et al: Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020.
11. Ara T, Teshima T, et al: Intestinal goblet cells protect against GVHD after allogeneic stem cell



-
- transplantation via Lypd8. *Sci Transl Med.* 2020
12. Mehta RS, Teshima T, et al: Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. *J Clin Oncol.* 2020.
 13. Zeiser R, Teshima T, et al: Ruxolitinib for Glucocorticoid-Refractory Chronic GVHD. *N Engl J Med.* 2021
 14. Chakraverty R, Teshima T: GVHD: a disorder of tissue regeneration and repair. *Blood.* 2021.
 15. Zeiser R, Teshima T: Nonclassical manifestations of acute GVHD. *Blood.* 2021.
 16. Schuster SJ, Teshima T, et al: Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021.
 17. Teshima T, Hill GR: The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models. *Front Immunol.* 2021.
 18. Yokota I, Teshima T: A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study. *Lancet Microbe.* 2021.
 19. Murata M, Teshima T: Treatment of Steroid-Refractory Acute GVHD Using Commercial Mesenchymal Stem Cell Products. *Front Immunol.* 2021.
 20. Fowler NH, Teshima T, et al: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med.* 2022.
 21. Ishio T, Teshima T, et al: Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma. *Blood.* 2022.
 22. Benjamin R, Teshima T, et al; CALM Study Group: UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. *Lancet Haematol.* 2022.
 23. Chiba M, Teshima T, et al: Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. *Blood.* 2022.
 24. Chen X, Teshima T, et al: Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota. *Proc Natl Acad Sci U S A.* 2022.
 25. Miklos DB, Teshima T, et al: Ibrutinib for First-Line Treatment of Chronic GVHD: Results From the Randomized Phase III iNTEGRATE Study. *J Clin Oncol.* 2023.
 26. Grupp SA, Teshima T, et al: Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. *Lancet Haematol.* 2023.
-